Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chicago, Illinois 60606


Phase II trial to study the effectiveness of vaccine therapy plus interleukin-2 in treating patients who have advanced melanoma. Vaccines made from a person's cancer cells may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Melanoma vaccine plus interleukin-2 may kill more cancer cells

Study summary:

PRIMARY OBJECTIVES: I. Determine clinical response rates in patients with advanced melanoma treated with gp100:209-217(210M) melanoma vaccine and low-dose interleukin-2. II. Assess response duration and progression-free intervals in these patients receiving this treatment. OUTLINE: Patients receive gp100:209-217(210M) emulsified in Montanide ISA-51 subcutaneously (SC) on day 1 and interleukin-2 SC on days 1-5 and 8-13. Courses repeat every 21 days in the absence of unacceptable toxicity or disease progression. Patients with a complete response (CR) receive 3 additional courses after achieving CR. Patients are followed every 9 weeks for 3 years or until disease recurrence. PROJECTED ACCRUAL: A total of 25-50 patients will be accrued for this study within 3.5 years.


Inclusion Criteria: - Histologically or cytologically confirmed cutaneous melanoma with clinical evidence of distant, metastatic, unresectable regional lymphatic, or extensive in-transit recurrent disease - HLA-A2*0201 positive by genotyping - Measurable disease as defined by the following: - At least 1 lesion accurately measured in at least 1 dimension - At least 20 mm by conventional techniques - At least 10 mm by spiral CT scan - Lesions considered intrinsically nonmeasurable include: - Bone lesions - Leptomeningeal disease - Ascites - Pleural/pericardial effusion - Inflammatory breast disease - Lymphangitis cutis/pulmonis - Abdominal masses not confirmed and followed by imaging techniques - Cystic lesions - Lesions situated in a previously irradiated area - No ocular or mucosal melanoma - No prior or concurrent liver or brain metastases - Performance status - ECOG 0-1 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 10 g/dL - LDH normal - Bilirubin normal - AST no greater than 2.5 times upper limit of normal - Creatinine normal - No congestive heart failure, angina, or symptomatic cardiac arrhythmia - No myocardial infarction within the past 6 months - No severe chronic pulmonary disease - Not pregnant or nursing - Fertile patients must use effective contraception - No primary or secondary immunodeficiency or autoimmune disease - No currently active second malignancy (e.g., patient has completed therapy and is considered unlikely to have recurrence within 1 year) other than nonmelanoma skin cancer - At least 4 weeks since prior immunotherapy - No prior interleukin-2 - No prior whole cell or gp100:209-217(210M)-targeted melanoma vaccine - No other concurrent cytokines or growth factors - At least 4 weeks since prior chemotherapy - At least 1 month since prior systemic corticosteroids - No concurrent systemic, inhaled, or topical corticosteroids - At least 1 month since other prior immunosuppressive medication - No antihypertensive medications from 1 day prior until 2 days after first course



Primary Contact:

Principal Investigator
John Roberts
Cancer and Leukemia Group B

Backup Contact:


Location Contact:

Chicago, Illinois 60606
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.